CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXHIBIT 10.22
LICENSE AGREEMENT
This Agreement is made and effective as of January 21, 1986, by and
between Gen-Probe, Inc., a California corporation with its principal place of
business located at 0000 Xxxxxxxxxx Xxxxx, Xxx Xxxxx, Xxxxxxxxxx 00000
("Gen-Probe"), Bioanalysis, Ltd., whose registered office is located at College
Buildings Courtenay Road Splott Cardiff ("Bioanalysis") and the University of
Wales College of Medicine ("UWCM") located at Xxxxx Xxxx, Xxxxxxx XX00XX.
RECITALS
WHEREAS, Bioanalysis has entered into a License Agreement with UWCM dated
July 12, 1984 (the "UWCM" Agreement") regarding certain University Patent
Rights (as hereafter defined) covering the UWCM Technology (as hereinafter
defined), and
WHEREAS, by virtue of the UWCM Agreement, Bioanalysis has acquired the
exclusive right and license to develop, manufacture, market and sell, either by
itself or with such other parties as UWSM and Bioanalysis shall determine, [***]
incorporating the UWCM Technology covered by the University Patent Rights, with
the right to grant sublicenses, and
WHEREAS, Bioanalysis also possesses certain other Bioanalysis Confidential
Information (as hereinafter defined) and may in the future possess certain
Bioanalysis Patent Rights (as hereinafter defined) relating to the UWCM
Technology, and
WHEREAS, Gen-Probe is desirous of obtaining from Bioanalysis, and
Bioanalysis is willing to grant to Gen-Probe, in accordance with the terms and
provisions of the UWSM Agreement, a world-wide, exclusive sublicense under the
University Patent Rights and a world-wide, exclusive license under the
Bioanalysis Confidential Information and Bioanalysis Patent Rights to exploit
such rights and know-how in the field of [***]:
NOW THEREFORE, the parties hereto agree as follows:
1. Definitions
A. "Affiliate" shall mean any entity at least fifty (50) percent of
which is owned or controlled by Gen-Probe.
B. "UNIVERSITY PATENT RIGHTS" shall mean the United States and
foreign patents set forth in Exhibit A, the United States and Foreign pending
patent applications set forth in Exhibit A, the United States and Foreign
Patents issuing from said pending United States and Foreign patent applications
or later-filed United States or Foreign applications based upon any of said
United States or Foreign patents or applications, any other patents or patent
applications which are now or hereafter licensed to Bioanalysis pursuant to the
UWCM Agreement, and any improvements, continuations, continuations-in-part,
divisions, reissues or extension of any of the foregoing.
C. "UWCM TECHNOLOGY" shall mean the technology covered by
*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-1-
the University Patent Rights, which consists of certain compounds, materials,
processes, and procedures relating to the use of stable derivatives of aryl
acridinium esters as labeling agents in chemiluminescent assays such that
(i)assay reagents may be labeled with such derivatives to very high densities,
and (ii) such labeled assay reagents, following the triggering of a light
emitting reaction, may be quantified or detected with high sensitivity by
measuring or sensing the emitted light through simple photon counters.
D. "BIOANALYSIS PATENT RIGHTS" shall mean any and all United States
Patents and Foreign Patents or Patent Applications now or hereafter owned by or
licensed to Bioanalysis (other than the University Patent
Rights) relating to the UWCM Technology and any improvements, continuations,
continuations-in-part, divisions, reissues or extensions of any of the
foregoing.
E. "BIOANALYSIS CONFIDENTIAL INFORMATION" shall mean and collectively
include all technical information which is now or hereafter owned by or
licensed to Bioanalysis which is not disclosed in the University Patent Rights
or Bioanalysis Patent Rights and which relates to the UWCM Technology, to the
extent that such information (a) was not known to Gen-Probe as of the date of
disclosure, or (b) was not and is not subsequently (i) disclosed in published
literature, or (ii) becomes generally available to industry, or (iii) is
subsequently obtained by Gen-Probe from a third party without binder of secrecy
upon Gen-Probe, provided, however, that Gen-Probe has no reason to believe that
such third party is in breach of any confidentiality obligations to Bioanalysis.
F. "CHEMILUMINESCENCE TECHNOLOGY" shall mean that body of knowledge
inclusive of (i)the Bioanalysis Confidential Information and (ii) any and all
knowledge now or hereafter disclosed in the University Patent Rights or
Bioanalysis Patent Rights.
G. "LICENSED PRODUCTS" shall mean [***].
H. "NET SALES" shall mean the invoiced price of Licensed Products sold
by Gen-Probe or its Affiliates less the applicable commissions, discounts,
allowances, returns, transportation costs, insurance charges, duties, and use,
value-added and sales taxes. In the event a Licensed Product is sold pursuant
to a reagent rental or comparable sale or lease program, that portion of the
invoiced price of such Licensed Product allocable to equipment/instrument
recovery accounts shall also be deducted in determining the Net Sales of such
Licensed Product, using generally accepted accounting principles consistently
applied. In the event a Licensed Product is sold in a combination package
containing other items, Net Sales, for purposes of payments on the combination
package, shall be calculated by multiplying the Net Sales of that combination
by the fraction A/(A+B)
*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-2-
where A is the net selling price for the Licensed Product sold separately
and A+B is the net selling price of the Licensed Product sold in combined form.
In the event that no such separate sales are made of the items in such a
combination package, Net Sales for the purpose of payments shall be calculated
by multiplying Net Sales of that combination package by the fraction C/(C+D)
where C is the fully allocated cost of the Licensed Product and D is the fully
allocated cost of such other items in the combination package, with such
standard costs being arrived at using Gen-Probe's standard accounting
procedures. With respect to the provisions relating to sales of combination
packages and products sold through reagent rental programs, Bioanalysis shall,
at its own cost and expense, have the right to review Gen-Probe's allocation and
standard accounting procedures through an independent certified public
accountant; provided, however,that such accountant shall only disclose
information revealed in such a review to Bioanalysis to the extent necessary to
procedures. Such review shall take place during regular business hours on the
premises of Gen-Probe's place of business upon reasonable notice of thirty (30)
days.
I. "GEN-PROBE CONFIDENTIAL INFORMATION" shall mean and collectively
include: (i) all business and technical information pertaining to Gen-Probe
which Bioanalysis may learn in connection with any audit of Gen Probe's records
or from any report by Gen-Probe furnished pursuant to the provisions of Sections
7 and 8 hereof; and (ii) all technical information which is disclosed in
confidence by Gen-Probe to Bioanalysis to the extent that such information (a)
was not known to Bioanalysis as of the date of disclosure (b) was not and is not
subsequently (i) disclosed in published literature, or (ii) becomes generally
available to industry, or (iii) is subsequently obtained by Bioanalysis from a
third party without binder of secrecy upon Bioanalysis, provided, however, that
Bioanalysis has no reason to believe that such third party is in breach of any
confidentiality obligations to Gen-Probe.
2. COMMENCEMENT AND DURATION
This Agreement shall commence in full force and effect on the 21st day of
January, nineteen hundred and eighty-six, and shall expire on the date of
expiration of the last to expire of the University Patent Rights or the
Bioanalysis Patent Rights and shall be construed accordingly.
3. GRANT
(i) In consideration of the covenants hereinafter contained
and the royalties hereinafter reserved, Bioanalysis hereby grants to Gen-Probe
and its Affiliates a world-wide, exclusive sublicense under the University
Patent Rights and a world-wide, exclusive license under the Bioanalysis Patent
Rights and Bioanalysis Confidential Information to develop, use, manufacture,
have manufactured, market and sell Licensed Products, and to practice the
processes and procedures of such Patent Rights and Confidential Information
for the purpose of the foregoing.
(ii) During the term of this Agreement, Gen-Probe shall have, subject to
the consent of Bioanalysis, which consent shall not be unreasonably withheld,
the right to sublicense any of the rights, privileges, and license granted
hereunder. Unless Bioanalysis objects to any proposed sublicense within thirty
(30) days of receiving notice thereof, it shall be deemed to consent to such
sublicense. In the event Gen-Probe sublicenses pursuant to this provision, any
and all royalties and consideration received under such sublicenses shall be
divided equally between Gen-Probe and Bioanalysis (subject, in the case of
Bioanalysis, to Bioanalysis' obligations under the UWCM Agreement).
(iii) Bioanalysis warrants that it is authorized, with the approval of
UWCM, to grant such a license as disclosed in this Agreement under the terms
and conditions of the UWCM Agreement. Bioanalysis further agrees to furnish a
true and correct copy of this Agreement within one month of its execution to
UWCM pursuant to paragraph 5 of the UWCM Agreement.
4. DISCLOSURE OF CHEMILUMINESCENCE TECHNOLOGY
(i) Bioanalysis shall, within thirty (30) days of the effective date of
this agreement and continuously thereafter, disclose to Gen-Probe all existing
Chemiluminescence Technology which is necessary or in any way useful to enable
Gen-Probe to develop, use, manufacture, have manufactured, market and sell
Licensed Products.
(ii) Gen-Probe and Bioanalysis shall continue to negotiate in good faith
a Development Agreement whereby Bioanalysis shall assist Gen-Probe in the
development of Licensed Products. In the event the parties hereto are unable to
agree upon the terms of such a Development Agreement within six months of the
effective date of this Agreement, then Gen-Probe shall promptly pay to
Bioanalysis the sum of [***].
5. CONFIDENTIALITY
(i) Both Bioanalysis and Gen-Probe hereby mutually agree to maintain
the Confidential Information of the other in the strictest confidence. Except
for the proper exercise of any license granted and rights reserved under the
provisions of this Agreement, each party agrees that it and its Affiliates will
not publish or otherwise divulge or use for its or their own benefit the
Confidential Information furnished to it by the other party without the
expressed written consent of the party providing such confidential information.
Both parties shall also cause its directors, officers, employees, and agents to
treat the Confidential Information of the other in a confidential manner and
not to utilize or disclose the same except as otherwise provided for in this
Agreement, and Gen-Probe shall require sublicensees to agree to treat
Bioanalysis Confidential Information in the same manner. The terms and
conditions of this clause shall not apply to Confidential Information which
ceases to be confidential pursuant to Sections 1 (E) and (I) hereof, but
otherwise shall survive the termination of this Agreement.
*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
6. Royalties
(i) Gen-Probe shall during the continuance of this Agreement make payments
on Net Sales of the Licensed Products according to the following schedule:
[***]
(ii) In the event Gen-Probe is obliged to pay a royalty to a third
party to develop, use, manufacture, have manufactured, market or sell a Licensed
Product subject to this Agreement, Gen-Probe may reduce its payment obligation
hereunder by an amount equal to the royalty to the third party, but, in no
event, shall the royalty owed Bioanalysis be reduced by more than [***].
(iii) Commencing with the first fiscal year of Gen-Probe beginning more
than three years from the effective date of this Agreement, a minimum royalty
(the "Minimum Royalty") must be paid to Bioanalysis by Gen-Probe in order to
maintain the exclusivity of the rights and licenses granted herein. The Minimum
Royalty shall be [***] per year for the first of such years, and [***] for
subsequent years. In the event the amount due on Net Sales of Licensed Products
is less than the Minimum Royalty for any such year, Gen-Probe may preserve the
exclusivity of the rights and license granted herein by also paying to
Bioanalysis the difference between the amount due on Net Sales of Licensed
Products for any such year and the Minimum Royalty, payable within sixty days of
the end of the fiscal year in question. In the event the total payment by
Gen-Probe is less than the Minimum Royalty for any such year, the exclusivity of
the rights and licenses granted herein shall cease.
7. Record-Keeping, Payment and Reports
(i) Gen-Probe and its affiliates shall maintain a complete and
accurate account of the amounts sold and Net Sales of all Licensed Products.
(ii) Within sixty (60) days after the end of each fiscal quarter (as
Gen-Probe may establish from time to time for its corporate operations)
Gen-Probe shall provide Bioanalysis with a written statement of Net Sales of
Licensed Products by Gen-Probe and Gen-Probe Affiliates, a calculation of
royalties owed, and a payment of the total amount then due. The first statement
shall be due after the first fiscal quarter in which the first sale of Licensed
Product occurs. Thereafter the report shall be made even if no royalty is due.
(iii) Bioanalysis at its own cost and expense and upon reasonable
sixty-day notice shall have access to and shall have the right through an
independent certified public accountant to inspect and make extracts from such
documents as necessary for Bioanalysis to ascertain the accuracy of the written
statement of Net Sales; provided, however, that such accountant shall only
disclose information revealed in such a review to Bioanalysis to the extent
necessary to
***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
- 5-
verify Gen-Probe's statement of Net Sales. In the event Bioanalysis ascertains
that the written statement of Net Sales is in error by greater than 10% and has
resulted in underpayment of royalties by Gen-Probe, Gen-Probe shall, in the
event it concurs with Bioanalysis' allegation of underpayment, promptly pay
Bioanalysis the underpaid amounts and reimburse Bioanalysis for all reasonable
expenses incurred by Bioanalysis in establishing such underpayment; provided,
however, that the amount of such expenses so reimbursed by Gen-Probe shall not
exceed [***]. In the event Gen-Probe disputes Bioanalysis' allegation of
underpayment, the parties shall engage in arbitration pursuant to Section 11
hereof.
(iv) In addition to its obligations under Section 5 hereof, Bioanalysis
agrees to hold in confidence all information concerning royalty payments and
sales by Gen-Probe. This obligation shall survive termination of this Agreement.
(v) Payment shall be made in U.S. currency. For payments based upon sales
outside of the United States, conversion of the payment to U.S. currency shall
be based on the average for the applicable quarter of the daily exchange rate
for the country of sale published in the Wall Street Journal.
(vi) All taxes which Gen-Probe or its Affiliates are required to withhold
form royalty payments shall be deducted from such payments and evidence of such
payments or withholding shall be delivered to Bioanalysis at the time the
accounting for the payment is made to Bioanalysis.
8. Scope of Agreement
(i) Gen-Probe understands that Bioanalysis has entered into an agreement
with Corning Medical (the "Corning Medical Agreement"), whereby Bioanalysis has
granted to Corning Medical an exclusive license under the UWCM Patent Rights and
certain Bioanalysis proprietary information in a field other than that which is
the subject of this Agreement. It is understood by the parties hereto that this
Agreement shall relate to the exploitation of the Chemiluminiscent Technology as
such may apply to [***]. Further expansion in the scope
of this Agreement may be considered by the parties hereto provided that (a)
there exists no overlap between this Agreement and the Corning Medical Agreement
or (b) in the event there is an overlap, a satisfactory agreement is obtained
between Gen-Probe, Bioanalysis and Corning Medical.
(ii) Notwithstanding Section 4 hereof, Bioanalysis shall not be required
hereunder to disclose to Gen-Probe any Bioanalysis Confidential Information
which is applicable only to the field of use which is the subject of the Corning
Medical Agreement or any Corning Medical confidential information obtained
pursuant to the Corning Medical Agreement.
9. Patents
Nothing in this Agreement shall be construed to prevent Bioanalysis or
Gen-Probe or its Affiliates from applying for patents for new techniques or
products for which Bioanalysis or Gen-Probe
*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to
the omitted portions.
-6-
and its Affiliates are responsible, and, except for the licensing rights
granted to Gen-Probe by this Agreement, any such techniques or products shall
be the sole and exclusive property of such responsible party. By way of
example, but not limitation, any and all improvements of the Chemiluminescent
Technology developed by Gen-Probe shall be the sole and exclusive property of
Gen-Probe, whether patentable or not. Gen-Probe shall, however, disclose to
Bioanalysis any such improvements; provided that Bioanalysis shall receive such
disclosures subject to its confidentiality obligations under this Agreement,
and shall have no rights to such improvements. Joint patents shall be the sole
and exclusive property of Gen-Probe, but Gen-Probe shall negotiate in good
faith with Bioanalysis for the payment of reasonable compensation to Bioanalysis
with respect to such joint patents, if such patents fall outside of the field
of use as described in Section 1(G) herein.
10. PATENT PROSECUTION
(i) Bioanalysis shall, to the extent permitted by the UWCM
Agreement, seek prompt issuance of and prosecute and maintain at its own
expense during the term of this Agreement the patent applications listed in
Schedule A and any patents issuing therefrom and any improvements,
continuations, continuations-in-part, divisions, reissues or extensions thereof.
(ii) Bioanalysis shall consult with Gen-Probe concerning the progress
and strategy of all patent prosecutions and furnish Gen-Probe bi-annual reports
summarizing the status of such prosecutions.
11. PATENT ENFORCEMENT
(i) UNIVERSITY PATENT RIGHTS.
(a) UWCM agrees to use all reasonable measures to enforce the
University Patent Rights against all infringers.
(b) Bioanalysis shall, pursuant to paragraph 18 (1) of the UWCM
Agreement, give notice in writing to UWCM (with full technical supporting
information) of any infringement or threatened infringement of the University
Patent Rights which shall at any time come to its knowledge.
(c) Pursuant to paragraph 18(2) of the UWCM Agreement, if UWCM
shall fail for a period of three (3) months after due notice in writing under
subsection (b) above has been given to UWCM of an infringement of the
University Patent Rights to institute proceedings necessary to prevent such
infringement and to indemnity Bioanalysis against all damages, claims, costs
and expenses in respect thereof, Bioanalysis shall be relieved from further
obligation to pay any royalties under the UWCM Agreement and shall be at
liberty at its own cost and expense to institute and prosecute any such action
or proceedings in the name of UWCM; provided, however, that if the
infringement or alleged infringement shall subsequently cease, royalties shall
become payable again as from the date of such cessation.
(d) If for any reason Bioanalysis shall fail to institute or
prosecute any such claim for infringement which UWCM has failed to pursue under
subsection (c) above, Gen-Probe shall, at its
sole option and discretion, but without obligation, have the right to pursue
such claim for infringement at its own cost and expense. Any recovery of
damages by Gen-Probe from such proceedings shall be the sole property of
Gen-Probe. No settlement, consent judgment, or other voluntary final
disposition of the suit may be entered into without the Consent of Bioanalysis,
which consent shall not be unreasonably withheld.
(e) In the event Gen-Probe exercises its option to proceed to
institute or prosecute such infringement proceedings under subsection (d)
above, Gen-Probe shall be relieved from further royalty payments under this
Agreement until such time as the infringement or alleged infringement shall
cease, at which time royalties shall become payable again as from the date of
such cessation.
(f) In the event of an infringement or infringements by third
parties of the University Patent Rights, and on a scale significantly affecting
Gen-Probe's sales of Licensed Products, and neither UWCM, nor Bioanalysis, nor
Gen-Probe shall elect to bring an infringement suit against such infringer, the
royalties hereunder payable by Gen-Probe shall be reduced by [***]; provided,
however, Gen-Probe shall present information to Bioanalysis that such infringer
shall have refused to enter into a sublicensing agreement with Gen-Probe.
(ii) BIOANALYSIS PATENT RIGHTS
(a) Bioanalysis agrees to use all reasonable measures to
enforce the Bioanalsysis Patent Rights against all infringers.
(b) Gen-Probe shall give notice in writing to Bioanalysis (with
full technical supporting information) of any infringement or threatened
infringement of the Bioanalysis Patent Rights which shall at any time come to
its knowledge.
(c) If Bioanalysis shall fail for a period of three (3) months
after due notice in writing under subsection (b) above has been given to
Bioanalysis of an infringement of the Bioanalysis Patent Rights to institute
proceedings necessary to prevent such infringement and to indemnify Gen-Probe
against all damages, claims, costs and expenses in respect thereof, the amount
of royalties payable by Gen-Probe hereunder shall be reduced by [***], and
Gen-Probe shall pay the remaining amount of royalties payable hereunder
directly to UWCM in fulfillment of its royalty obligations hereunder, and shall
be at liberty at its own cost and expense to institute and prosecute any such
action or proceedings in the name of Bioanalysis, provided, however, that if the
infringement of alleged infringement shall subsequently cease, royalties shall
become payable again as from the date of such cessation. Any recovery of
damages by Gen-Probe from such proceedings shall be the sole property of
Gen-Probe. No settlement, consent judgement, or other voluntary final
disposition of the suit may be entered into without the Consent of Bioanalysis,
which consent shall not be unreasonably withheld.
(d) In the event of an infringement or infringements by third
parties of the Bioanalysis Patent Rights, and on a scale significantly
affecting Gen-Probe's sales of Licensed Products, and neither UWCM, nor
Bioanalysis, nor Gen-Probe shall elect to bring an
***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
infringement suit against such infringer, the royalties hereunder payable by
Gen-Probe shall be reduced by [***]; provided, however, Gen-Probe shall present
information to Bioanalysis that such infringer shall have refused to enter into
a sublicensing agreement with Gen-Probe.
12. Termination
(i) In the event that any of the University or Bioanalysis Patent
Rights are found to be invalid, and such finding permits others to practice the
Chemiluminescence Technology in a significant way, Gen-Probe may terminate this
Agreement upon ninety (90) days written notice to Bioanalysis.
(ii) This Agreement may be terminated by either Bioanalysis or
Gen-Probe for breach or default of the other. Such termination shall be
effective sixty (60) days after written notice is delivered to the breaching
party unless the breach or default is cured prior to the expiration of the sixty
(60) day period. This Agreement may not be terminated in the event of
disagreement between the parties as to the amount of royalties due. In the event
of such disagreement, if resolution cannot be achieved between the parties, the
parties agree to engage in a procedure of binding arbitration in New York City
in accordance with the Rules of the American Arbitration Association before a
panel of three arbitrators familiar with the technology and business to which
this Agreement relates. One arbitrator shall be chosen by each of the parties
and a third selected by the two chosen by the parties. Both parties shall share
the cost associated with the arbitration equally; provided, however, that in the
event the amount claimed to be owed by Gen-Probe is in error by greater than 10%
and such error has or would have resulted in underpayment of royalties by
Gen-Probe, Gen-Probe shall bear all costs associated with the arbitration and
the travel, room, and board expenses incurred by Bioanalysis in attending the
arbitration; provided further, however, that all such costs and expenses payable
solely by Gen-Probe shall not exceed [***], and that the remainder of the costs
associated with the arbitration shall be shared equally.
(iii) Upon termination of this Agreement for any reason, nothing herein
shall be construed to release either party of any obligation which matured prior
to the effective date of such termination, and Gen-Probe and/or any sublicensee
thereof may, after the effective date of such termination, sell all Licensed
Products, and complete Licensed Products in the process of manufacture at the
time of such termination and sell the same, provided that Gen-Probe pays to
Bioanalysis the royalties thereon as required by this Agreement and submits the
reports required by this Agreement on the sales of Licensed Products. Further,
upon termination for any reason, all sublicenses executed by Gen-Probe shall not
terminate and shall automatically be assigned to Bioanalysis who shall be
substituted for Gen-Probe as sublicensor. Gen-Probe shall take all reasonable
steps as may be requested by Bioanalysis to effect such assignments.
(iv) In the event that the UWCM Agreement is terminated for any
reason prior to the termination date of this Agreement, whether
*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-9-
through breach of default of Bioanalysis or otherwise, this Agreement shall not
terminate or lapse, but all the rights and obligations of Bioanalysis shall be
automatically assigned and delegated to UWCM, who shall be substituted for
Bioanalysis as licensor and sublicensor hereunder, and this Agreement shall
remain in full force and effect by and between UWCM and Gen-Probe. In the event
of any dispute between UWCM and Bioanalysis as to which Gen-Probe owes an
obligation, Gen-Probe shall have the right to discharge that obligation to UWCM
and such discharge shall be to the extent deemed full satisfaction of its
obligation to Bioanalysis. If such obligation is a royalty obligation,
Gen-Probe can deduct a payment made to UWCM from any royalty owed Bioanalysis
as provided under this Agreement.
13. Infringement
Bioanalysis shall defend, indemnify and hold Gen-Probe harmless from
and against any and all claims, liabilities, expenses, damages, costs,
attorneys' fees, judgments or decrees that may be incurred by Gen-Probe as a
result of claims of infringement or ownership arising out of Gen-Probe's
exercise of the rights granted to it by this Agreement up to and including 100%
of royalties which shall become due subsequent to the date of assertion of any
such claims. In the event Bioanalysis fails to defend, indemnify or hold
Gen-Probe harmless as provided above, Gen-Probe shall be relieved from further
obligation to pay royalties until such time as the dispute is resolved, and
shall have the option, but no obligation, to take over the defense of said
dispute, the expenses of which, including all damages incurred by Gen-Probe in
connection therewith, shall be credited against royalties which become payable
to Bioanalysis subsequent to the date of assertion of any such claims.
14. Breach by Affiliate
A breach of this Agreement by an Affiliate of Gen-Probe shall be
deemed to be a breach by Gen-Probe.
15. Assignment
Gen-Probe may assign or otherwise transfer this Agreement and the
licenses granted hereby and the rights acquired by it hereunder so long as such
assignment or transfer are accompanied by a sale or other transfer of
Gen-Probe's entire business or of that part of Gen-Probe's business to which
the licenses granted hereby relates. In the event of such assignment or
transfer, Gen-Probe shall require the assignee or transferee to agree in
writing to be bound by the terms and provisions of this Agreement.
16. Government Laws, Codes and Regulations
Gen-Probe and Gen-Probe Affiliates shall have sole responsibility for
compliance with all laws, codes and regulations pertaining to the Licensed
Products, their manufacture, use and marketing. Gen-Probe Affiliates shall bear
all expenses, fees and costs with regard to obtaining approvals to comply with
any of said laws, codes and regulations in all countries covered by this
Agreement.
17. Applicable Laws
This Agreement shall be construed and governed by the laws
-10-
of the State of California (except as it may necessarily be subject to the
Patent Laws of the United States).
18. Severability
The parties hereto do not intend to violate any public policy,
statutory or common law. However, if any sentence, paragraph, clause or
combination of this Agreement contravenes any state or federal law or is found
to be otherwise unenforceable by a court from which there is no appeal, or no
appeal is taken, such sentences, paragraphs, clauses or combinations of the
same shall be deleted and the remainder of this Agreement shall remain binding.
19. Notices
All notices required or provided for use in this Agreement shall be
in writing and shall be given by certified mail and properly addressed to the
address of the party to be served as shown below. Notice shall be effective
upon the date upon which such notice is mailed.
If mailed to Bioanalysis:
Dr. J. Xxxxxx Xxxxxxxx
Bioanalysis Ltd.
College Buildings Courtenay Road
P.O. Box 00
Xxxxxxxxxx Xxxxx
Xxxxxxx XX0 0XX
Xxxxxx Xxxxxxx
If to Gen-Probe:
Xx. Xxxxxx X. Xxxxxxxx
Executive Vice President
Gen-Probe Incorporated
0000 Xxxxxxxxxx Xxxxx
Xxx Xxxxx, XX 00000
If to UWCM:
Xxxxxxxxx X. Xxxxxx, Xxxxxxx
University of Wales College of Medicine
Xxxxxxx XX0 0XX
Xxxxxx Xxxxxxx
20. Integration
This Agreement constitutes the entire understanding between the
parties with respect to the subject matter hereof and shall supercede all
previous communications, presentations, understandings and agreements, either
oral or written, between the parties or any official or representative thereof
with respect to the subject matter of this Agreement. This Agreement may be
amended or
-11-
modified only by a written document executed by all of the parties hereto.
IN WITNESS THEREOF, the parties hereunto have affixed their authorized
signatures.
UNIVERSITY OF WALES COLLEGE BIOANALYSIS, LTD.
OF MEDICINE
By: /s/ By: /s/ J. Xxxxxx Xxxxxxxx
-------------------------- ----------------------
Title: Academic Registrar Title: Director
------------------ ---------------
Date: 1/21/86 Date: 1/21/86
------------------- ----------------
GEN-PROBE, INC.
By: /s/ Xxxxxx X. Xxxxxxxx
----------------------
Title: Vice President
---------------
Date: 1/21/86
----------------
-12-
SCHEDULE A
[Four Pages of Technical Information Deleted Pursuant to Confidential Treatment
Request]
